High-dose carmustine and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell lung carcinoma

D. A. Rushing, W. R. Friedenberg, M. C. Baldauf, S. Broste, J. A. Gehlsen, D. H. Kriesel, D. P. Koontz, K. A. Rodvold

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fourteen patients with small cell carcinoma of the lung in relapse or with disease refractory to chemotherapy were treated with carmustine (BCNU) at doses of 600 to 1000 mg/m2 intravenously followed by autologous bone marrow transplantation. All patients previously were treated with cyclophosphamide, doxorubicin, vincristine, and etoposide. Seven of the 14 patients responded to the high-dose BCNU (50% response with 95% confidence limits ranging from 23% to 77%). Three patients had a complete response, and four had a partial response. Regrowth of tumor occurred within 60 days of treatment in the responding patients. Death occurred in six patients before the recovery of the platelet count to 50,000 cells/μl. Although the response rate was high, the toxicity was excessive. In the dosage range of 600 to 1000 mg/m2 in heavily pretreated patients, BCNU is not recommended, but additional investigation may be warranted in patients with central nervous system metastases who previously were treated with radiation therapy.

Original languageEnglish (US)
Pages (from-to)720-724
Number of pages5
JournalCancer
Volume68
Issue number4
StatePublished - 1991
Externally publishedYes

Fingerprint

Carmustine
Small Cell Lung Carcinoma
Bone Marrow
Therapeutics
Autologous Transplantation
Vincristine
Etoposide
Bone Marrow Transplantation
Platelet Count
Doxorubicin
Cyclophosphamide
Radiotherapy
Central Nervous System
Neoplasm Metastasis
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rushing, D. A., Friedenberg, W. R., Baldauf, M. C., Broste, S., Gehlsen, J. A., Kriesel, D. H., ... Rodvold, K. A. (1991). High-dose carmustine and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell lung carcinoma. Cancer, 68(4), 720-724.

High-dose carmustine and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell lung carcinoma. / Rushing, D. A.; Friedenberg, W. R.; Baldauf, M. C.; Broste, S.; Gehlsen, J. A.; Kriesel, D. H.; Koontz, D. P.; Rodvold, K. A.

In: Cancer, Vol. 68, No. 4, 1991, p. 720-724.

Research output: Contribution to journalArticle

Rushing, DA, Friedenberg, WR, Baldauf, MC, Broste, S, Gehlsen, JA, Kriesel, DH, Koontz, DP & Rodvold, KA 1991, 'High-dose carmustine and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell lung carcinoma', Cancer, vol. 68, no. 4, pp. 720-724.
Rushing DA, Friedenberg WR, Baldauf MC, Broste S, Gehlsen JA, Kriesel DH et al. High-dose carmustine and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell lung carcinoma. Cancer. 1991;68(4):720-724.
Rushing, D. A. ; Friedenberg, W. R. ; Baldauf, M. C. ; Broste, S. ; Gehlsen, J. A. ; Kriesel, D. H. ; Koontz, D. P. ; Rodvold, K. A. / High-dose carmustine and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell lung carcinoma. In: Cancer. 1991 ; Vol. 68, No. 4. pp. 720-724.
@article{37bb3aff448f48c19e9e7024b12fd917,
title = "High-dose carmustine and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell lung carcinoma",
abstract = "Fourteen patients with small cell carcinoma of the lung in relapse or with disease refractory to chemotherapy were treated with carmustine (BCNU) at doses of 600 to 1000 mg/m2 intravenously followed by autologous bone marrow transplantation. All patients previously were treated with cyclophosphamide, doxorubicin, vincristine, and etoposide. Seven of the 14 patients responded to the high-dose BCNU (50{\%} response with 95{\%} confidence limits ranging from 23{\%} to 77{\%}). Three patients had a complete response, and four had a partial response. Regrowth of tumor occurred within 60 days of treatment in the responding patients. Death occurred in six patients before the recovery of the platelet count to 50,000 cells/μl. Although the response rate was high, the toxicity was excessive. In the dosage range of 600 to 1000 mg/m2 in heavily pretreated patients, BCNU is not recommended, but additional investigation may be warranted in patients with central nervous system metastases who previously were treated with radiation therapy.",
author = "Rushing, {D. A.} and Friedenberg, {W. R.} and Baldauf, {M. C.} and S. Broste and Gehlsen, {J. A.} and Kriesel, {D. H.} and Koontz, {D. P.} and Rodvold, {K. A.}",
year = "1991",
language = "English (US)",
volume = "68",
pages = "720--724",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - High-dose carmustine and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell lung carcinoma

AU - Rushing, D. A.

AU - Friedenberg, W. R.

AU - Baldauf, M. C.

AU - Broste, S.

AU - Gehlsen, J. A.

AU - Kriesel, D. H.

AU - Koontz, D. P.

AU - Rodvold, K. A.

PY - 1991

Y1 - 1991

N2 - Fourteen patients with small cell carcinoma of the lung in relapse or with disease refractory to chemotherapy were treated with carmustine (BCNU) at doses of 600 to 1000 mg/m2 intravenously followed by autologous bone marrow transplantation. All patients previously were treated with cyclophosphamide, doxorubicin, vincristine, and etoposide. Seven of the 14 patients responded to the high-dose BCNU (50% response with 95% confidence limits ranging from 23% to 77%). Three patients had a complete response, and four had a partial response. Regrowth of tumor occurred within 60 days of treatment in the responding patients. Death occurred in six patients before the recovery of the platelet count to 50,000 cells/μl. Although the response rate was high, the toxicity was excessive. In the dosage range of 600 to 1000 mg/m2 in heavily pretreated patients, BCNU is not recommended, but additional investigation may be warranted in patients with central nervous system metastases who previously were treated with radiation therapy.

AB - Fourteen patients with small cell carcinoma of the lung in relapse or with disease refractory to chemotherapy were treated with carmustine (BCNU) at doses of 600 to 1000 mg/m2 intravenously followed by autologous bone marrow transplantation. All patients previously were treated with cyclophosphamide, doxorubicin, vincristine, and etoposide. Seven of the 14 patients responded to the high-dose BCNU (50% response with 95% confidence limits ranging from 23% to 77%). Three patients had a complete response, and four had a partial response. Regrowth of tumor occurred within 60 days of treatment in the responding patients. Death occurred in six patients before the recovery of the platelet count to 50,000 cells/μl. Although the response rate was high, the toxicity was excessive. In the dosage range of 600 to 1000 mg/m2 in heavily pretreated patients, BCNU is not recommended, but additional investigation may be warranted in patients with central nervous system metastases who previously were treated with radiation therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025953771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025953771&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 720

EP - 724

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -